Table 4.
Characteristics and medical costs of patients with 12 month-follow-up period pre- and post-BT initiation
| Total | BT-naïve | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ADL | IFX | UST | Sub total |
ADL | IFX | UST | Subtotal | ||
| Number of patients | 18 | 20 | 37 | 77 | 14 | 19 | 30 | 64 | |
| Average Age | 47.7 | 46.5 | 46.2 | 46.8 | 49.6 | 47.3 | 46.3 | 47.5 | |
| %Female | 11.1% | 20.0% | 16.2% | 15.6% | 14.3% | 21.1% | 20.0% | 18.8% | |
| Cost (pre) | ¥760 | ¥950 | ¥900 | ¥886 | ¥365 | ¥916 | ¥603 | ¥641 | |
| In 1000 JPY unit |
IP | ¥18 | ¥343 | ¥254 | ¥235 | ¥0 | ¥361 | ¥162 | ¥188 |
| OP | ¥513 | ¥301 | ¥425 | ¥405 | ¥133 | ¥261 | ¥216 | ¥210 | |
| RX | ¥229 | ¥306 | ¥221 | ¥246 | ¥232 | ¥294 | ¥225 | ¥244 | |
| Cost increase | ¥1538 | ¥2429 | ¥1865 | ¥1907 | ¥1853 | ¥2494 | ¥2221 | ¥2187 | |
| In 1000 JPY unit |
IP | ¥95 | ¥601 | - ¥37 | ¥156 | ¥146 | ¥633 | ¥21 | ¥228 |
| OP | ¥1077 | ¥1958 | ¥2011 | ¥1754 | ¥1379 | ¥1974 | ¥2296 | ¥1965 | |
| RX | ¥366 | - ¥130 | - ¥109 | - ¥2 | ¥328 | - ¥113 | - ¥96 | - ¥5 | |
ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, cost increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs